secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0001171843-25-000796
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 5.03, 3.02, 3.03, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech announces $15M private placement led by Velan Capital; appoints David Liu to board
--------------------------------------------------------------------------------

- Gross proceeds of $15M from sale of Series B-1 convertible preferred shares ($10K each) and 3.47M common shares at $1.92/share.
- Proceeds to fund Phase 2 study of EB06 (CXCL10 antibody) for nonsegmental vitiligo and for working capital.
- Velan Capital led placement; officers/directors purchased ~$1.1M of securities.
- David Liu, Senior Analyst at Velan Capital, appointed to Board of Directors effective immediately.
- Company to file resale registration statement within 30 days; beneficial ownership cap of 4.99% (or 9.99% opt-in).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000117184325000796/0001171843-25-000796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000117184325000796/f8k_021225.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-000796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer